Abstract:ABSTRACT Major histocompatibility complex class II (MHC-II) molecules play a central role in adaptive antiviral immunity by presenting viral peptides to CD4 + T cells. Due to their key role in adaptive immunity, many viruses, including Kaposi's sarcoma-associated herpesvirus (KSHV), have evolved multiple strategies to inhibit the MHC-II antigen presentation pathway. The expression of MHC-II, which is controlled mainly at the level of transcription, is strictly dependent upon the binding of the class II transactivator (CIITA) to the highly conserved promoters of all MHC-II genes. The recruitment of CIITA to MHC-II promoters requires its direct interactions with a preassembled MHC-II enhanceosome consisting of cyclic AMP response element-binding protein (CREB) and nuclear factor Y (NF-Y) complex and regulatory factor X (RFX) complex proteins. Here, we show that KSHV-encoded latency-associated nuclear antigen (LANA) disrupts the association of CIITA with the MHC-II enhanceosome by binding to the components of the RFX complex. Our data show that LANA is capable of binding to all three components of the RFX complex, RFX-associated protein (RFXAP), RFX5, and RFX-associated ankyrin-containing protein (RFXANK), in vivo but binds more strongly with the RFXAP component in in vitro binding assays. Levels of MHC-II proteins were significantly reduced in KSHV-infected as well as LANA-expressing B cells. Additionally, the expression of LANA in a luciferase promoter reporter assay showed reduced HLA-DRA promoter activity in a dose-dependent manner. Chromatin immunoprecipitation assays showed that LANA binds to the MHC-II promoter along with RFX proteins and that the overexpression of LANA disrupts the association of CIITA with the MHC-II promoter. These assays led to the conclusion that the interaction of LANA with RFX proteins interferes with the recruitment of CIITA to MHC-II promoters, resulting in an inhibition of MHC-II gene expression. Thus, the data presented here identify a novel mechanism used by KSHV to downregulate the expressions of MHC-II genes. IMPORTANCE Kaposi's sarcoma-associated herpesvirus is the causative agent of multiple human malignancies. It establishes a lifelong latent infection and persists in infected cells without being detected by the host's immune surveillance system. Only a limited number of viral proteins are expressed during latency, and these proteins play a significant role in suppressing both the innate and adaptive immunities of the host. Latency-associated nuclear antigen (LANA) is one of the major proteins expressed during latent infection. Here, we show that LANA blocks MHC-II gene expression to subvert the host immune system by disrupting the MHC-II enhanceosome through binding with RFX transcription factors. Therefore, this study identifies a novel mechanism utilized by KSHV LANA to deregulate MHC-II gene expression, which is critical for CD4 + T cell responses in order to escape host immune surveillance.

Carboxyl-terminal amino acids 1052 to 1082 of the latency-associated nuclear antigen (LANA) interact with RBP-Jκ and are responsible for LANA-mediated RTA repression.

The Single RBP-Jκ Site Within the LANA Promoter is Crucial for Establishing Kaposi's Sarcoma-Associated Herpesvirus Latency During Primary Infection

Kaposi's Sarcoma-Associated Herpesvirus LANA Recruits the DNA Polymerase Clamp Loader to Mediate Efficient Replication and Virus Persistence

Kaposi's sarcoma herpesvirus latency-associated nuclear antigen broadly regulates viral gene expression and is essential for lytic infection

Comprehensive Analysis of LANA Interacting Proteins Essential for Viral Genome Tethering and Persistence.

Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly Through Binding with the Regulatory Factor X Complex.

Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell cycle arrest

Kaposi's Sarcoma-Associated Herpesvirus Latent Protein LANA Interacts with HIF-1α to Upregulate RTA Expression During Hypoxia: Latency Control under Low Oxygen Conditions

Kaposi's sarcoma-associated herpesvirus (KSHV) LANA prevents KSHV episomes from degradation

A Unique SUMO-2-interacting Motif Within LANA is Essential for KSHV Latency.

MLL1 is Regulated by KSHV LANA and is Important for Virus Latency

Kaposi's sarcoma-associated herpesvirus-encoded LANA recruits topoisomerase IIβ for latent DNA replication of the terminal repeats

Kaposi's Sarcoma-Associated Herpesvirus-Encoded LANA Can Interact with the Nuclear Mitotic Apparatus Protein to Regulate Genome Maintenance and Segregation

Endoplasmic Reticulum-Shaping Atlastin Proteins Facilitate KSHV Replication

Cytoplasmic isoforms of Kaposi sarcoma herpesvirus LANA recruit and antagonize the innate immune DNA sensor cGAS

The RBP-Jκ binding sites within the RTA promoter regulate KSHV latent infection and cell proliferation.

EC5S Ubiquitin Complex is Recruited by KSHV Latent Antigen LANA for Degradation of the VHL and P53 Tumor Suppressors.

A Potential Alpha-Helix Motif In The Amino Terminus Of Lana Encoded By Kaposi'S Sarcoma-Associated Herpesvirus Is Critical For Nuclear Accumulation Of Hif-1 Alpha In Normoxia

A herpesvirus transactivator and cellular POU proteins extensively regulate DNA binding of the host Notch signaling protein RBP-Jκ to the virus genome

H2AX Phosphorylation is Important for LANA-Mediated Kaposi's Sarcoma-Associated Herpesvirus Episome Persistence

Bub1 and Cenp-F Can Contribute to Kaposi'S Sarcoma-Associated Herpesvirus Genome Persistence by Targeting Lana to Kinetochores